Semaglutide dose and dosage in the studies
The unit, the formulation and the population give an amount its meaning. These are reported study quantities.
Semaglutide dose
Semaglutide's clinical research contains several amounts because it contains several questions. STEP 1 studied subcutaneous 2.4 mg once weekly in adults with overweight or obesity without diabetes. SUSTAIN-6 used 0.5 or 1.0 mg once weekly in people with type 2 diabetes at high cardiovascular risk. FLOW used 1.0 mg weekly in type 2 diabetes with chronic kidney disease.
Putting the population beside the amount helps me understand why that quantity was studied. A number extracted from one of those trials loses its purpose surprisingly quickly. It cannot choose treatment for a person whose history, other medicines and tolerability are absent from the page.
The research also used gradual escalation. In the pooled STEP tolerability analysis, gastrointestinal events were concentrated around that period. That explains the attention paid to tolerability as an amount increased. It supplies no schedule for an individual to follow.
Oral Semaglutide
The tablet combines semaglutide with SNAC, an absorption enhancer. The formulation review describes temporary changes near the tablet that help the peptide cross the stomach wall. Bioavailability—the share that reaches circulation—is about 0.4–1%. That small fraction helps explain why oral and injected milligram amounts cannot simply be exchanged.
Diabetes studies used daily oral 3 mg, 7 mg and 14 mg amounts; higher-dose research also tested 25 mg and 50 mg. These are quantities reported in research, with separate formulation and trial conditions. The oral formulation required fasting and limited water to achieve the studied absorption. Personal administration instructions come from the prescribed product's current label and the pharmacist.
The chemical ingenuity impresses me. So does the stubbornness of the delivery problem: a peptide that works once it reaches its receptor still has to reach the blood. That is a different question from how much fat or lean mass disappears during treatment.
Elimination half-life
Both oral and subcutaneous semaglutide have an approximately one-week elimination half-life, with persistence in circulation for roughly five weeks after the final dose. Albumin binding and resistance to enzymatic breakdown account for that long stay.
Half-life describes a decline in concentration. It gives no exact deadline for a symptom to disappear, and a missed injection does not immediately clear the medicine. I think the duration becomes most useful when it explains a clinical caution, such as why pregnancy planning needs a conversation well in advance. It becomes misleading when treated as a precise personal countdown.
A review of interactions with oral medicines found low overall risk from delayed gastric emptying, while advising particular caution for drugs with a narrow therapeutic range. The presence of other medicines can therefore matter even when a general interaction summary sounds reassuring.
Semaglutide dosage and syringe units
Syringe units describe a volume marking. Milligrams describe the amount of drug. The concentration is needed to relate them, so the same marking can correspond to different amounts in different preparations. A question about 40 units has no universal milligram answer. A pharmacist has to identify the preparation and read its label.
A conversion stripped of those facts worries me, particularly when a familiar compound name encourages the assumption that the liquid contents must match. The clinical trials reported a specified manufactured preparation and amounts in milligrams. They did not establish one conversion for every container.
Compounded Semaglutide
A compounding pharmacy prepares compounded semaglutide; that preparation has no FDA approval. During the shortage from roughly 2022 to early 2025, pharmacies could help fill gaps; the broad shortage-related compounding pathway was curtailed after the shortage was declared resolved in early 2025.
The current safety account includes dosing errors, hospitalizations and preparations with unverified ingredients. Those concerns cannot be settled by the molecular formula printed alongside a name. The large weight, cardiovascular and kidney trials studied the manufactured medicine. Their results do not establish equivalence for a compounded preparation.
For me, the composition question starts here as well: the actual substance, its concentration and its formulation have to be known before an amount can mean anything useful.